CG Oncology, Inc. — fact timeline

CG Oncology, Inc. shareholders approved Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation at the 2026-06-04 meeting.

“Proposal 4: Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation The Company’s stockholders indicated, on an advisory basis, their preference for the frequency of stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 66,962,791 4,269 537,270 116,996 16,216,685”

CG Oncology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-04 meeting.

“Proposal 3: Advisory Vote on Executive Compensation The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The final voting results are as follows: Shares Voted For Shares Voted Against Abstentions Broker Non-Votes 65,894,959 1,603,011 123,356 16,216,685”

CG Oncology, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.

“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Shares Voted For Shares Voted Against Abstentions 83,711,522 4,103 122,386”

CG Oncology, Inc. shareholders approved Election of Class II Directors at the 2026-06-04 meeting.

“Proposal 1: Election of Directors The Company’s stockholders elected the two persons listed below as Class II directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Shares Voted For Shares Voted Withhold Broker Non-Votes Name of Directors Elected Christina Rossi 67,531,501 89,825 16,216,685 Victor Tong, Jr. 62,401,874 5,219,452 16,216,685”

Arthur Kuan was appointed as President at CG Oncology, Inc..

“On May 20, 2026, the Company’s Board of Directors also approved the appointment of Arthur Kuan as President of the Company, in addition to his other positions, in connection with Mr. Bellete’s separation.”

Ambaw Bellete departed as President & Chief Operating Officer at CG Oncology, Inc..

“On May 20, 2026, CG Oncology, Inc. (the “ Company ”) and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026.”

CG Oncology, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $60.2 million, or $(0.71) per share, EPS $(0.71) per share.

“an increase in personnel-related expenses, including compensation costs from increased headcount, and an increase in professional and consulting fees. • Net Loss : Net loss was $60.2 million, or $(0.71) per share, for the first quarter of 2026, as compared to a net loss of $34.5 million, or $(0.45) per share, for the prior year period.”

CG Oncology, Inc. reported the first quarter ended March 31, 2024 results: net income $16.9 million, or ($0.36) per share, EPS ($0.36) per share.

“CG Oncology, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.”

CG Oncology, Inc.: Adopted amended and restated bylaws establishing procedures for stockholder proposals and director nominations, and conforming to the restated certificate (effective 2024-01-29).

“On January 29, 2024, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Company’s board of directors to become effective upon the effectiveness of the Restated Certificate, became effective.”

CG Oncology, Inc.: Amended and restated certificate of incorporation to increase authorized common stock, authorize preferred stock, establish classified board, require supermajority vote for director removal, eliminate stockholder written consent, and designate exclusive federal forum for Securities Act claims (effective 2024-01-29).

“On January 29, 2024, CG Oncology, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.”